Autolus Therapeutics ( (AUTL) ) has issued an announcement.
Autolus Therapeutics reported its financial results for the year ended December 31, 2024, highlighting significant achievements such as the FDA approval and U.S. commercial launch of AUCATZYL® for adult B-cell acute lymphoblastic leukemia. The company has authorized 33 treatment centers as of March 19, 2025, and aims to expand further in the U.S. and new markets while advancing its clinical pipeline. Autolus also anticipates regulatory decisions in the EU and UK for obe-cel and is progressing with trials in autoimmune diseases. Financially, the company ended 2024 with increased cash reserves, driven by a strategic collaboration with BioNTech, despite reporting a net loss of $220.7 million.
More about Autolus Therapeutics
Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies. The company is primarily engaged in the biopharmaceutical industry, with a market focus on innovative CAR T cell therapies for cancer and autoimmune diseases.
YTD Price Performance: -26.24%
Average Trading Volume: 1,220,599
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $476.4M
Find detailed analytics on AUTL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com